Table 1:
Presenting features and initial therapy
| Characteristics of Cohort | Total Cohort | Initial Therapy† | p-value† | ||||
|---|---|---|---|---|---|---|---|
| ALL | AML | ||||||
| N | % | N | % | N | % | ||
| Overall | 54 | 100 | 39 | 75.0 | 13 | 25.0 | 0.0003 |
| Age | |||||||
| <10 years | 35 | 64.8 | 26 | 66.7 | 7 | 53.8 | 0.510 |
| ≥10 years | 19 | 35.2 | 13 | 33.3 | 6 | 46.2 | |
| Sex | |||||||
| Female | 26 | 48.1 | 21 | 53.8 | 4 | 30.8 | 0.205 |
| Male | 28 | 51.9 | 18 | 46.2 | 9 | 69.2 | |
| Presenting WBC | |||||||
| <100×103 /uL | 37 | 68.5 | 29 | 74.4 | 7 | 53.8 | 0.362 |
| ≥100×103 /uL | 8 | 14.8 | 5 | 12.8 | 3 | 23.1 | |
| Unknown | 9 | 16.7 | 5 | 12.8 | 3 | 23.1 | |
| CNS involvement at diagnosis | |||||||
| CNS negative | 30 | 55.6 | 23 | 59.0 | 6 | 46.1 | 0.748 |
| CNS positive‡ | 14 | 25.9 | 10 | 25.6 | 4 | 30.8 | |
| Unknown | 10 | 18.5 | 6 | 15.4 | 3 | 23.1 | |
| Cytogenetic abnormalities | |||||||
| Neutral | 36 | 66.7 | 26 | 66.7 | 8 | 61.5 | 0.087 |
| Favorable§ | 5 | 9.2 | 5 | 12.8 | 0 | 0.0 | |
| Unfavorable§ | 9 | 16.7 | 7 | 17.9 | 2 | 15.4 | |
| Not tested | 4 | 7.4 | 1 | 2.6 | 3 | 23.1 | |
| MPAL Phenotype | |||||||
| B/Myeloid | 33 | 61.1 | 26 | 66.7 | 7 | 53.8 | 0.517 |
| T/Myeloid | 19 | 35.2 | 11 | 28.2 | 6 | 46.2 | |
| B/T/Myeloid | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | |
| B/T | 2 | 3.7 | 2 | 5.1 | 0 | 0.0 | |
| MPAL Lineage | |||||||
| Bi-Phenotypic | 25 | 46.3 | 19 | 48.7 | 6 | 46.2 | 0.441 |
| Bi- or Tri-Lineal | 25 | 46.3 | 18 | 46.2 | 5 | 38.5 | |
| Indeterminate | 4 | 7.4 | 2 | 5.1 | 2 | 15.4 | |
†
Does not include sparse data for hybrid induction (n=2/54, 3.7%). Fisher’s exact test.
‡
Blasts present on cerebrospinal fluid cytospin or clinical involvement (e.g. cranial nerve findings).
§
Favorable (Trisomies 4&10 n=4, chromosomes >50, n=1), Unfavorable (KMT2A gene rearrangement n=4, BCR-ABL n=2, intrachromosomal amplification of chromosome 21 n=0, chromosomes <44 and/or DNA index <0.81 n=3, recurrent AML genetic findings n=0).